Close Menu

NEW YORK (GenomeWeb) – The field of personalized medicine has been suffering from a credibility problem. More than a decade after the completion of the Human Genome Project, some are disappointed at the limited number of new life-extending treatments that have resulted from the nearly $3 billion effort. The stewards of the HGP had overpromised what could be gleaned from the human biological blueprint, critics have said, wondering where all the cures are.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Stephen Hahn, the nominee to lead the US Food and Drug Administration, underwent a Senate confirmation hearing yesterday, the Washington Post reports.

The US Food and Drug Administration has approved an RNA interference drug to treat acute hepatic porphyria.

Gizmodo looks over the past decade of consumer DNA testing to find the field to be lacking.

In Nature this week: native RNA sequencing and analysis of a human poly(A) transcriptome, nanopore sequencing-based method to analyze short tandem repeat expansions, and more.